Video Cannot be Displayed
Questions? See video help section or contact web support
The Most TAVR Experience in the Philadelphia Region
The transcatheter aortic valve replacement (TAVR) is a promising new treatment for patients with severe aortic stenosis (narrowing of the heart valve) who are not ideal candidates for traditional open heart surgery.
The Hospital of the University of Pennsylvania (HUP) was one of 23 hospitals nationwide that participated in the FDA regulated clinical trial examining the use of this minimally invasive procedure as part of a clinical trial (PARTNER Trial).
- HUP successfully performed its first TAVR procedure in November 2007
- Nearly 1,000 TAVR procedures have been performed at Penn Medicine
- Penn was the first in the Philadelphia region to perform TAVR
- Penn is the most experienced provider of TAVR in Philadelphia
- Approved by the FDA in November of 2011, TAVR is now being offered to eligible patients.
Breaking New Ground with TAVR
Penn is now involved in the next phase of TAVR trials, which is testing the 3rd generation of transcatheter valve therapy using the SAPIEN 3 valve, a smaller profile delivery system.
The co-principal investigators for this trial at the University of Pennsylvania are Joseph E. Bavaria, MD, director of the Thoracic Aortic Surgery Program and Howard C. Herrmann, MD, director of the Interventional Cardiology and Cardiac Catheterization Laboratories.
For frequently asked questions about TAVR, formerly known as Transcatheter Aortic Valve Implantation (TAVI), see our TAVR FAQ below.
TAVR Frequently Asked Questions
Need an appointment? Request one online 24 hours/day, 7 days/week or call 800-789-PENN (7366) to speak to a referral counselor.